Selected article for: "ADE antibody dependent enhancement and infection enhance"

Author: Sugiarto, Sarah; Spiri, Andrea M.; Riond, Barbara; Novacco, Marilisa; Oestmann, Angelina; de Miranda, Luisa H. Monteiro; Meli, Marina L.; Boretti, Felicitas S.; Hofmann-Lehmann, Regina; Willi, Barbara
Title: Passive immunization does not provide protection against experimental infection with Mycoplasma haemofelis
  • Document date: 2016_8_5
  • ID: 1uw8xcxw_54
    Snippet: It could be argued that the use of the homologous Mhf isolate for experimental challenge of the recipient cats that had been used to infect the plasma donor cats contributed to the more pronounced immune response in the passively immunized cats. This has been reported for other feline pathogens, i.e. feline coronavirus (FCoV) which can cause feline infectious peritonitis (FIP) [44] . During the pathogenesis of FIP, the virus targets macrophages a.....
    Document: It could be argued that the use of the homologous Mhf isolate for experimental challenge of the recipient cats that had been used to infect the plasma donor cats contributed to the more pronounced immune response in the passively immunized cats. This has been reported for other feline pathogens, i.e. feline coronavirus (FCoV) which can cause feline infectious peritonitis (FIP) [44] . During the pathogenesis of FIP, the virus targets macrophages and infection of these cells can be enhanced in the presence of antibodies (antibody-dependent enhancement, ADE) [45] . Takano et al. [44] showed that cats passively immunized with antibodies to serotype I FCoV showed an enhanced onset of disease following inoculation with the homologous serotype; this was not found when cats passively immunized with antibodies to serotype II FCoV were challenged with serotype I. The authors concluded that FCoV re-infection with the same serotype might induce ADE and could advance the development of FIP. Although ADE has also been suspected in bacterial infection [46] , it is unknown whether it might play a role in the pathogenesis of feline hemoplasma infections [15] . Signs of infection enhancement have recently been documented in "Candidatus M. turicensis"-recovered, seropositive cats following a challenge with Mhf [15] . The study suggested that the presence of antibodies directed against CMt could enhance Mhf infection. However, to the best of our knowledge, disease enhancement after rechallenge with the same feline hemoplasma species has not been documented. In contrast, two studies showed that cats that had recovered from Mhf or CMt infection were protected from re-infection following re-challenge with the same hemoplasma species, respectively [27, 28] . Both studies had used an aliquot of the same Mhf or CMt isolate for re-infection that had been used for primary infection of the cats (personal communication, RHL).

    Search related documents:
    Co phrase search for related documents
    • ADE antibody dependent enhancement and antibody presence: 1, 2, 3, 4, 5
    • ADE antibody dependent enhancement and bacterial infection: 1
    • ADE antibody dependent enhancement and cell infection: 1, 2, 3, 4, 5, 6, 7
    • ADE antibody dependent enhancement and disease enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ADE antibody dependent enhancement and enhanced onset: 1
    • ADE antibody dependent enhancement and FCoV feline coronavirus: 1, 2
    • ADE antibody dependent enhancement and feline coronavirus: 1, 2, 3, 4, 5
    • ADE antibody dependent enhancement and feline infectious peritonitis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • ADE antibody dependent enhancement and feline pathogen: 1
    • ADE antibody dependent enhancement and FIP development: 1
    • ADE antibody dependent enhancement and FIP feline infectious peritonitis: 1, 2, 3, 4
    • ADE antibody dependent enhancement and FIP pathogenesis: 1
    • ADE antibody dependent enhancement and homologous serotype: 1
    • ADE antibody dependent enhancement and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • ADE antibody dependent enhancement and infection enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
    • ADE antibody dependent enhancement and infectious peritonitis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • ADE antibody dependent enhancement and primary infection: 1, 2, 3
    • ADE antibody dependent enhancement and serotype infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ADE induce and antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11